Floatz logo

Idarubicine

Leukemia

Affiliated Hospital of Nantong UniversityPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
65/ 100

Competitive context

124 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 3BB
FILGRASTIM
Hospital General de Mexico
Phase 4BB

View all 50 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →